Genmab A/S Sponsored ADR (GMAB) – What Are Investment Firms Saying About This Stock?

Shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB) have been assigned an average recommendation of “Moderate Buy” from the twelve brokerages that are presently covering the firm, MarketBeat reports. Two analysts have rated the stock with a hold recommendation, nine have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $53.61.

Several analysts have recently issued reports on the company. Guggenheim upped their price target on Genmab A/S from $58.00 to $80.00 and gave the stock a “buy” rating in a research note on Friday. HC Wainwright raised their price objective on Genmab A/S from $50.00 to $70.00 and gave the company a “buy” rating in a research note on Thursday. Truist Financial reissued a “buy” rating and issued a $67.00 price objective (up from $45.00) on shares of Genmab A/S in a research note on Thursday. Weiss Ratings upgraded Genmab A/S from a “hold (c)” rating to a “hold (c+)” rating in a report on Tuesday, September 1st. Finally, New Street Research set a $43.00 target price on Genmab A/S in a research report on Wednesday, July 22nd.

Genmab A/S Price Performance

Genmab A/S stock opened at $57.06 on Monday. The company has a market capitalization of $35.61 billion, a P/E ratio of 44.93, a P/E/G ratio of 2.28 and a beta of 0.72. The firm’s fifty day simple moving average is $37.12 and its 200-day simple moving average is $30.58. The company has a current ratio of 2.46, a quick ratio of 2.44 and a debt-to-equity ratio of 0.81. Genmab A/S has a 1-year low of $23.62 and a 1-year high of $59.97.

Genmab A/S (NASDAQ:GMAB) last released its quarterly earnings data on Thursday, August 6th. The company reported $0.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.37 by $0.17. The business had revenue of $1.16 billion during the quarter, compared to analyst estimates of $1.12 billion. Genmab A/S had a net margin of 19.08% and a return on equity of 14.89%. Sell-side analysts forecast that Genmab A/S will post 1.22 earnings per share for the current fiscal year.

Institutional Trading of Genmab A/S

A number of institutional investors and hedge funds have recently modified their holdings of the company. First Trust Advisors LP raised its holdings in Genmab A/S by 84.3% in the 1st quarter. First Trust Advisors LP now owns 2,461,342 shares of the company’s stock worth $66,038,000 after acquiring an additional 1,126,069 shares during the period. Renaissance Technologies LLC lifted its position in Genmab A/S by 26.4% during the 1st quarter. Renaissance Technologies LLC now owns 4,414,550 shares of the company’s stock worth $118,442,000 after acquiring an additional 921,700 shares during the last quarter. SummitTX Capital L.P. bought a new stake in Genmab A/S during the first quarter valued at about $2,263,000. Legacy Wealth Asset Management LLC boosted its holdings in Genmab A/S by 164.1% during the second quarter. Legacy Wealth Asset Management LLC now owns 102,164 shares of the company’s stock valued at $2,806,000 after acquiring an additional 63,484 shares during the period. Finally, Advisors Preferred LLC bought a new stake in Genmab A/S during the first quarter valued at about $1,361,000. 7.07% of the stock is currently owned by institutional investors and hedge funds.

More Genmab A/S News

Here are the key news stories impacting Genmab A/S this week:

• Positive Sentiment: Genmab reported that its cancer drug reduced the risk of death by 50% in a head-and-neck cancer trial and met the study’s primary goals. The results could strengthen the drug’s commercial prospects and support potential changes to treatment standards. Genmab drug cuts death risk 50% in head and neck cancer trial
• Positive Sentiment: Analysts raised their valuation expectations: Guggenheim increased its price target to $80 from $58 and maintained a Buy rating; Morgan Stanley raised its target to $57 from $42 while retaining an Equal Weight rating; and Goldman Sachs initiated or reiterated a Buy recommendation. Guggenheim analyst recommendation Genmab receives a Buy from Goldman Sachs
• Positive Sentiment: Truist reaffirmed its Buy rating and lifted its target to $67 from $45, while HC Wainwright raised its target to $70 from $50. HC Wainwright also maintained a Buy rating, suggesting analysts see additional upside despite the recent rally. HC Wainwright analyst recommendation
• Positive Sentiment: Coverage describing Genmab as potentially undervalued after its trial successes adds to the bullish narrative around the company’s pipeline and long-term growth prospects. Can Genmab still be undervalued after its trial wins?

Genmab A/S Company Profile

Genmab A/S is a biotechnology company headquartered in Copenhagen, Denmark, focused on discovering and developing differentiated antibody-based medicines for the treatment of cancer and other serious diseases. The company uses proprietary antibody technologies, including DuoBody and HexaBody, to create therapies designed to engage the immune system or target specific disease-related proteins.

Genmab’s marketed and partnered products include DARZALEX (daratumumab) for multiple myeloma, developed with Johnson & Johnson; EPKINLY (epcoritamab) for certain types of B-cell lymphoma, developed with AbbVie; and Tivdak (tisotumab vedotin) for cervical cancer, developed with Seagen.